(This Nov. 23rd story corrects fiscal year of expected regulatory approval in the 10th paragraph to March-end 2021, not March-end 2020) By Rocky Swift (Reuters) – Japan’s biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes... More »
JERUSALEM (Reuters) – Israel’s Together Pharma said on Tuesday it will set up a new company with Premier Dead Sea to sell cosmetics based on cannabis and Dead Sea minerals. The firm said the products would be based on CBD, or Cannabidiol — a constitute of the ... More »
(Reuters) – The U.S. health regulator approved GW Pharmaceuticals Plc’s epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis. The... More »
(Reuters) – Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial. The company said it would now focus on developing othe... More »
(Reuters) – GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday i... More »
Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs. More »
A unit of China's Fosun Group and Shanghai Pharmaceuticals Holding Co (601607.SS) are among bidders for a stake in U.S. speciality drugmaker Arbor Pharmaceuticals LLC, the companies said on Monday. More »
A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to preven... More »
Kite Pharma Inc said on Monday it planned to launch in the fourth quarter of this year a Phase 2 trial of its experimental T-cell therapy in leukemia patients, possibly at a lower dose than is currently being tested. More »
Logos of Japanese Takeda Pharmaceutical Co are seen at an office building in Glattbrugg near Zurich March 7, 2012. REUTERS/Arnd Wiegmann/File Photo – RTX2RH16 Japan’s Takeda Pharmaceutical Co (4502.T) flagged its appetite for fresh acquisitions to bolster its ... More »
Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments. More »
A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology (ASH), where clinical trial results will help clarify their potential for doctors and investors. More »
Herve Brailly, CEO of Innate Pharma, attends the Reuters Biotech summit in Paris June 3, 2009. REUTERS/John Schults France’s Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent f... More »
Pfizer Inc (PFE.N) is buying Anacor Pharmaceuticals Inc (ANAC.O) in a $5.2 billion deal to add an eczema gel to its portfolio, a month after the U.S. drug major scrapped plans to buy Allergan Plc (AGN.N). Anacor shares rose 54 percent to $98.60 in premarket tr... More »
MUMBAI India’s largest drugmaker Sun Pharmaceutical Industries Ltd has been warned by U.S. health regulators for violating manufacturing standards at its Halol plant in India, even as it has been working on fixing issues at the plant for over a year. The U.S. ... More »
MUMBAI The U.S. Food and Drug Administration has revoked an approval issued in March to India’s Sun Pharma Advanced Research Company Ltd (SPARC) to launch a drug for seizures, citing manufacturing quality problems at its production site. The move comes as a se... More »
